Cargando…

Design of an Optimized Wilms' Tumor 1 (WT1) mRNA Construct for Enhanced WT1 Expression and Improved Immunogenicity In Vitro and In Vivo

Tumor antigen–encoding mRNA for dendritic cell (DC)-based vaccination has gained increasing popularity in recent years. Within this context, two main strategies have entered the clinical trial stage: the use of mRNA for ex vivo antigen loading of DCs and the direct application of mRNA as a source of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Benteyn, Daphné, Anguille, Sébastien, Van Lint, Sandra, Heirman, Carlo, Van Nuffel, An MT, Corthals, Jurgen, Ochsenreither, Sebastian, Waelput, Wim, Van Beneden, Katrien, Breckpot, Karine, Van Tendeloo, Viggo, Thielemans, Kris, Bonehill, Aude
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2013
Materias:	Methods - Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3889186/ https://www.ncbi.nlm.nih.gov/pubmed/24253259 http://dx.doi.org/10.1038/mtna.2013.54

Ejemplares similares

Characterization of CD8(+) T-Cell Responses in the Peripheral Blood and Skin Injection Sites of Melanoma Patients Treated with mRNA Electroporated Autologous Dendritic Cells (TriMixDC-MEL)
por: Benteyn, Daphné, et al.
Publicado: (2013)

Mutation or loss of Wilms' tumor gene 1 (WT1) are not major reasons for immune escape in patients with AML receiving WT1 peptide vaccination
por: Busse, Antonia, et al.
Publicado: (2010)

Overcoming HLA restriction in clinical trials: Immune monitoring of mRNA-loaded DC therapy
por: Van Nuffel, An M.T., et al.
Publicado: (2012)

The Wilms’ tumor (WT1) gene: Methods and protocols
por: Agrawal, Suraksha
Publicado: (2018)

Wilms’ Tumour gene 1 (WT1) as an immunotherapeutic target
por: Coosemans, A.
Publicado: (2011)

Wilms Tumor-1 (WT1) rs16754 Polymorphism
por: Sookaromdee, Pathum, et al.
Publicado: (2019)

Implications of the Wilms’ Tumor Suppressor Wt1 in Cardiomyocyte Differentiation
por: Wagner, Nicole, et al.
Publicado: (2021)

Long term efficacy of WT1 peptide vaccine in patients with WT1 overexpressing hematopoeitic and solid malignancies
por: Letsch, Anne, et al.
Publicado: (2013)

A high incidence of WT1 abnormality in bilateral Wilms tumours in Japan, and the penetrance rates in children with WT1 germline mutation
por: Kaneko, Y, et al.
Publicado: (2015)

Wilms’ Tumour 1 (WT1) peptide vaccination in patients with acute myeloid leukaemia induces short-lived WT1-specific immune responses
por: Uttenthal, Benjamin, et al.
Publicado: (2014)

TSA downregulates Wilms tumor gene 1 (Wt1) expression at multiple levels
por: Makki, Mohammad Shahidul, et al.
Publicado: (2008)

Nephron, Wilms’ tumor-1 (WT1), and synaptopodin expression in developing podocytes of mice
por: Kato, Takashi, et al.
Publicado: (2017)

mRNA: From a chemical blueprint for protein production to an off-the-shelf therapeutic
por: Van Lint, Sandra, et al.
Publicado: (2013)

Chemotherapy and terminal skeletal muscle differentiation in WT1‐mutant Wilms tumors
por: Royer‐Pokora, Brigitte, et al.
Publicado: (2018)

Every Beat You Take—The Wilms′ Tumor Suppressor WT1 and the Heart
por: Wagner, Nicole, et al.
Publicado: (2021)

Diagnostic utility of Wilms’ tumour-1 protein (WT-1) immunostaining in paediatric renal tumours
por: Goyal, Surbhi, et al.
Publicado: (2016)

Studies of Wilms’ Tumor (WT1) Gene Expression in Adult Acute Leukemias in Singapore
por: Lim, Che Kang, et al.
Publicado: (2007)

The Wilms tumor protein Wt1 contributes to female fertility by regulating oviductal proteostasis
por: Nathan, Abinaya, et al.
Publicado: (2017)

Evidence for susceptibility genes to familial Wilms tumour in addition to WT1, FWT1 and FWT2
por: Rapley, E A, et al.
Publicado: (2000)

Wilms’ tumor 1 (WT1) as a prognosis factor in gynecological cancers: A meta-analysis
por: Lu, Jingjing, et al.
Publicado: (2018)

Wilms Tumor-1 (WT1) rs16754 Polymorphism and Clinical Outcome in Acute Myeloid Leukemia
por: Ramzi, Mani, et al.
Publicado: (2019)

The zinc finger domain of Wilms' tumor 1 suppressor gene (WT1) behaves as a dominant negative, leading to abrogation of WT1 oncogenic potential in breast cancer cells
por: Han, Youqi, et al.
Publicado: (2007)

Comprehensive Biology and Genetics Compendium of Wilms Tumor Cell Lines with Different WT1 Mutations
por: Royer-Pokora, Brigitte, et al.
Publicado: (2020)

TERT Expression in Wilms Tumor Is Regulated by Promoter Mutation or Hypermethylation, WT1, and N-MYC
por: Jablonowski, Carolyn M., et al.
Publicado: (2022)

Long-term kidney function in children with Wilms tumour and constitutional WT1 pathogenic variant
por: Falcone, Maria Pia, et al.
Publicado: (2021)

WT1 peptide analogue WT1-126Y enhances leukemia lysis
por: Alqudaihi, Ghofran, et al.
Publicado: (2014)

Association of WT1 IgG antibody against WT1 peptide with prolonged survival in glioblastoma multiforme patients vaccinated with WT1 peptide
por: Oji, Yusuke, et al.
Publicado: (2016)

Deletion of WT1 and WIT1 Genes and Loss of Heterozygosity on Chromosome 11p in Wilms Tumors in Japan
por: Kaneko, Yasuhiko, et al.
Publicado: (1993)

WT1-AS promotes cell apoptosis in hepatocellular carcinoma through down-regulating of WT1
por: Lv, Long, et al.
Publicado: (2015)

Human CLEC9A antibodies deliver Wilms' tumor 1 (WT1) antigen to CD141(+) dendritic cells to activate naïve and memory WT1‐specific CD8(+) T cells
por: Pearson, Frances E, et al.
Publicado: (2020)

The Wilms' Tumor Suppressor Protein WT1 Is Processed by the Serine Protease HtrA2/Omi
por: Hartkamp, Jörg, et al.
Publicado: (2010)

The Wilms’ tumor gene (WT1) regulates E-cadherin expression and migration of prostate cancer cells
por: Brett, Adina, et al.
Publicado: (2013)

Deducing the stage of origin of Wilms' tumours from a developmental series of Wt1-mutant mice
por: Berry, Rachel L., et al.
Publicado: (2015)

Expression of the Wilms' Tumor Gene WT1 in Solid Tumors and Its Involvement in Tumor Cell Growth
por: Oji, Yusuke, et al.
Publicado: (1999)

The Wilms Tumor Gene wt1a Contributes to Blood-Cerebrospinal Fluid Barrier Function in Zebrafish
por: Hopfenmüller, Vera L., et al.
Publicado: (2022)

Cytotoxicity of WT1-reactive T cells against Wilms tumor: An implication for antigen-specific adoptive immunotherapy
por: Monzavi, Seyed Mostafa, et al.
Publicado: (2023)

Morphoproteomic Profiling of the Mammalian Target of Rapamycin (mTOR) Signaling Pathway in Desmoplastic Small Round Cell Tumor (EWS/WT1), Ewing’s Sarcoma (EWS/FLI1) and Wilms’ Tumor(WT1)
por: Subbiah, Vivek, et al.
Publicado: (2013)

Wilms' tumor 1 (WT1) expression and prognosis in solid cancer patients: a systematic review and meta-analysis
por: Qi, Xiao-wei, et al.
Publicado: (2015)

Testis formation in XX individuals resulting from novel pathogenic variants in Wilms’ tumor 1 (WT1) gene
por: Eozenou, Caroline, et al.
Publicado: (2020)

Loss of heterozygosity at 11p13 in Wilms' tumours does not necessarily involve mutations in the WT1 gene.
por: Cowell, J. K., et al.
Publicado: (1993)

Cannot write session to /tmp/vufind_sessions/sess_cde27dhjs4j1kta2oiccqsfno3